- Home
- KALV vs APEI Comparison
KALV vs APEI Comparison
Compare KALV & APEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- APEI
- Stock Information
- Founded
- KALV N/A
- APEI 1991
- Country
- KALV United States
- APEI United States
- Employees
- KALV N/A
- APEI N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- APEI Other Consumer Services
- Sector
- KALV Health Care
- APEI Consumer Discretionary
- Exchange
- KALV Nasdaq
- APEI Nasdaq
- Market Cap
- KALV 796.4M
- APEI 660.7M
- IPO Year
- KALV N/A
- APEI 2007
- Fundamental
- Price
- KALV $11.10
- APEI $35.63
- Analyst Decision
- KALV Strong Buy
- APEI Strong Buy
- Analyst Count
- KALV 8
- APEI 7
- Target Price
- KALV $26.43
- APEI $38.00
- AVG Volume (30 Days)
- KALV 1.5M
- APEI 206.8K
- Earning Date
- KALV 12-04-2025
- APEI 11-03-2025
- Dividend Yield
- KALV N/A
- APEI N/A
- EPS Growth
- KALV N/A
- APEI 321.15
- EPS
- KALV N/A
- APEI 1.05
- Revenue
- KALV $1,426,000.00
- APEI $644,549,000.00
- Revenue This Year
- KALV N/A
- APEI $7.21
- Revenue Next Year
- KALV $209.38
- APEI $4.33
- P/E Ratio
- KALV N/A
- APEI $34.78
- Revenue Growth
- KALV N/A
- APEI 5.50
- 52 Week Low
- KALV $7.30
- APEI $14.01
- 52 Week High
- KALV $17.28
- APEI $39.83
- Technical
- Relative Strength Index (RSI)
- KALV 38.98
- APEI 45.72
- Support Level
- KALV $10.75
- APEI $36.12
- Resistance Level
- KALV $12.23
- APEI $39.07
- Average True Range (ATR)
- KALV 0.62
- APEI 1.41
- MACD
- KALV -0.01
- APEI -0.48
- Stochastic Oscillator
- KALV 23.41
- APEI 0.00
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About APEI American Public Education Inc.
American Public Education Inc provides online and campus based postsecondary education including various undergraduate and graduate degree programs. The fields of study include business administration, health science, technology, criminal justice, education, liberal arts, national security, military studies, intelligence, and homeland security. There are three reporting segments: the American Public University segment which is the key revenue generator; the Rasmussen University Segment and the Hondros College of Nursing segment. The revenue is generated from net course registrations and enrollment, tuition rate, net tuition, and other fees.